Clinical trial · Observational
Long-term Treatment Outcome for Stage III NPC Patients and Risk Grouping by Plasma EBV DNA
Long-term Treatment Outcome for Stage III Nasopharyngeal Carcinoma Patients and Risk Grouping by Plasma Epstein-Barr Virus DNA
NCT03314051CI-TRIAL-00029986completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
No previous study reported the treatment outcome of stage III nasopharyngeal carcinoma (NPC) patients. The investigators try to investigate the long-term treatment outcome of stage III NPC patients and do risk grouping by plasma Epstein-Barr virus (EBV) DNA assay for future therapy improvement.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| EBV Related Carcinoma | EBV-Related Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Nasopharyngeal Carcinoma | Nasopharyngeal Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Overall survival (OS)
- timeFrame
- 5 year
- description
- Diagnosis to death
Secondary outcomes (3)
- measure
- Progression-free survival (PFS)
- timeFrame
- 5 year
- description
- Diagnosis to death to recurrence or metastasis
- measure
- Distant metastasis failure-free survival (DMFFS)
- timeFrame
- 5 year
- description
- Diagnosis to death to distant metastasis
- measure
- Locoregional failure-free survival (LRFFS)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Biopsy-proven stage III nasopharyngeal carcinoma (NPC) * Finished curative chemoradiotherapy * Have Pre-treatment and post-radiotherapy plasma EBV DNA Exclusion Criteria: * No tissue proven NPC * Not finished curative treatment * No Pre-treatment and post- radiotherapy plasma EBV DNA
References
Publications (0)
Data not yet available
No reference posted for this study.